Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Fluoroquinolone Fight With Public Citizen Will Continue Despite New Warning

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA is requiring a boxed warning and a medication guide for the antibiotics due to the risk of tendon injuries but is not mandating a letter to doctors as requested in Public Citizen’s lawsuit.

You may also be interested in...

FDA Adds Black Box Warning To Label For Conventional Antipsychotics

Physicians advised of increased mortality risk when the drugs are used off-label to treat psychosis in elderly dementia patients.

Levaquin, Cipro Should Have “Black Box” On Tendon Rupture, Public Citizen Urges

Warning "buried" in the adverse reactions section of labeling for fluoroquinolones is insufficient, Public Citizen says in petition to FDA.

New York State To Conduct Its Own Review Of COVID-19 Vaccines In Another Blow To FDA’s Reputation

Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts